Ariosa Diagnostics sera présent et interviendra lors de la 16e Conférence internationale sur le diagnostic prénatal et la thérapie (International Conference on Prenatal Diagnosis and Therapy)

Télécharger le fichier PDF

San Jose, Calif., May 29, 2012 – Ariosa Diagnostics, Inc., a molecular diagnostics company, today announced it will be presenting two studies and also exhibiting as a meeting sponsor at the upcoming ISPD 16th International Conference on Prenatal Diagnosis and Therapy in Miami Beach, Fla.

The first study will be a poster presentation titled, “Analysis of Maternal Age, Gestational Age and Aneuploidy on Fraction of Fetal Cell Free DNA.” The study examines how maternal age, gestational age and trisomy status affects the fetal fraction of cell free DNA. The abstract, #P1-64, will be presented on June 4, 12:15-1:15pm EST, by Craig Struble, PhD, director of bioinformatics at Ariosa Diagnostics.

The second study will be an oral presentation titled, “Clinical Evaluation of a Directed cfDNA Analysis Method for Non-Invasive Prenatal Fetal Trisomy Detection.” The abstract will be presented on June 5, between 8:30-10:30am EST, by Ken Song, MD, chief executive officer at Ariosa Diagnostics.

Ariosa Diagnostics developed the HarmonyTM Prenatal Test, which will be broadly available through a partnership with LabCorp and Integrated Genetics. The Harmony Prenatal Test is performed using a simple maternal blood draw and detects fetal trisomy via analysis of cell-free DNA.